Portal de Periódicos da CAPES

Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases

2012; American Medical Association; Volume: 308; Issue: 1 Linguagem: Inglês

10.1001/jama.2012.7304

1538-3598

Jie Zhang, Fenglong Xie, Elizabeth Delzell, Lang Chen, Kevin Winthrop, James D. Lewis, Kenneth G. Saag, John W. Baddley, Jeffrey R. Curtis,

Peripheral Neuropathies and Disorders

ERPES ZOSTER (HZ), CAUSED by the reactivation of latent varicella-zoster virus (VZV), manifests as an acute, painful vesicular rash and is often accompanied by chronic pain or postherpetic neuralgia. 1In the United States, the incidence rate of HZ in the unvaccinated general population 50 years or older is estimated to be 7.0 cases per 1000 person-years. 2A live attenuated vaccine reduces HZ risk by 70% and 51% among immunocompetent individuals 50 to 59 years and 60 years and older in 2 randomized blinded trials, respectively. 3,4he Advisory Committee on Immunization Practices (ACIP) recommends a single dose of the zoster vaccine for all people 60 years or older. 5][10] Currently, the Food and Drug Administration (FDA), the ACIP, and the American College of Rheumatology consider the live HZ vaccine to be contraindicated in patients receiving some immunosuppressive medications commonly used to treat these conditions, including all immune-modulating biologic agents;